Opium (Opioid) Addiction – Pipeline Review, H1 2012
Reference Code: GMDHC1895IDB
Publication Date: March 2012
Opium (Opioid) Addiction – Pipeline Review, H1 2012 GMDHC1895IDB / Pub March 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(1)
Opium (Opioid) Addiction – Pipeline Review, H1 2012
Table of Contents
Table of Contents ............................................................................................................................................................................... 2
List of Tables ................................................................................................................................................................................. 6
List of Figures ................................................................................................................................................................................ 7
Introduction......................................................................................................................................................................................... 8
Global Markets Direct Report Coverage ........................................................................................................................................ 8
Opium (Opioid) Addiction Overview ................................................................................................................................................... 9
Therapeutics Development............................................................................................................................................................... 10
An Overview of Pipeline Products for Opium (Opioid) Addiction ................................................................................................. 10
Opium (Opioid) Addiction Therapeutics under Development by Companies .................................................................................... 12
Opium (Opioid) Addiction Therapeutics under Investigation by Universities/Institutes ..................................................................... 14
Late Stage Products ......................................................................................................................................................................... 16
Comparative Analysis .................................................................................................................................................................. 16
Mid Clinical Stage Products.............................................................................................................................................................. 17
Comparative Analysis .................................................................................................................................................................. 17
Early Clinical Stage Products ........................................................................................................................................................... 18
Comparative Analysis .................................................................................................................................................................. 18
Pre-Clinical Stage Products.............................................................................................................................................................. 19
Comparative Analysis .................................................................................................................................................................. 19
Opium (Opioid) Addiction Therapeutics – Products under Development by Companies.................................................................. 20
Opium (Opioid) Addiction Therapeutics – Products under Investigation by Universities/Institutes ................................................... 21
Companies Involved in Opium (Opioid) Addiction Therapeutics Development................................................................................. 22
Nanotherapeutics, Inc.................................................................................................................................................................. 22
Catalyst Pharmaceutical Partners, Inc......................................................................................................................................... 23
Titan Pharmaceuticals, Inc. ......................................................................................................................................................... 24
Orexo AB ..................................................................................................................................................................................... 25
Camurus AB ................................................................................................................................................................................ 26
Omeros Corporation .................................................................................................................................................................... 27
KYORIN Pharmaceutical Co., Ltd................................................................................................................................................ 28
TheraQuest Biosciences, LLC ..................................................................................................................................................... 29
Opium (Opioid) Addiction – Therapeutics Assessment .................................................................................................................... 30
Assessment by Monotherapy Products ....................................................................................................................................... 30
Assessment by Combination Products ........................................................................................................................................ 31
Assessment by Route of Administration ...................................................................................................................................... 32
Assessment by Molecule Type .................................................................................................................................................... 34
Drug Profiles..................................................................................................................................................................................... 36
NanoBUP - Drug Profile .............................................................................................................................................................. 36
Product Description................................................................................................................................................................. 36
Mechanism of Action ............................................................................................................................................................... 36
R&D Progress ......................................................................................................................................................................... 36
MN-166 - Drug Profile .................................................................................................................................................................. 37
Product Description................................................................................................................................................................. 37
Mechanism of Action ............................................................................................................................................................... 37
Opium (Opioid) Addiction – Pipeline Review, H1 2012 GMDHC1895IDB / Pub March 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(2)
Opium (Opioid) Addiction – Pipeline Review, H1 2012
R&D Progress ......................................................................................................................................................................... 37
CPP-109 - Drug Profile ................................................................................................................................................................ 39
Product Description................................................................................................................................................................. 39
Mechanism of Action ............................................................................................................................................................... 39
R&D Progress ......................................................................................................................................................................... 39
OX219 - Drug Profile ................................................................................................................................................................... 41
Product Description................................................................................................................................................................. 41
Mechanism of Action ............................................................................................................................................................... 41
R&D Progress ......................................................................................................................................................................... 41
Lofexidine - Drug Profile .............................................................................................................................................................. 42
Product Description................................................................................................................................................................. 42
Mechanism of Action ............................................................................................................................................................... 42
R&D Progress ......................................................................................................................................................................... 42
Lofexidine + Marinol - Drug Profile .............................................................................................................................................. 43
Product Description................................................................................................................................................................. 43
Mechanism of Action ............................................................................................................................................................... 43
R&D Progress ......................................................................................................................................................................... 43
CPP-115 - Drug Profile ................................................................................................................................................................ 44
Product Description................................................................................................................................................................. 44
Mechanism of Action ............................................................................................................................................................... 44
R&D Progress ......................................................................................................................................................................... 44
Probuphine - Drug Profile ............................................................................................................................................................ 45
Product Description................................................................................................................................................................. 45
Mechanism of Action ............................................................................................................................................................... 45
R&D Progress ......................................................................................................................................................................... 45
Methadone - Drug Profile ............................................................................................................................................................ 47
Product Description................................................................................................................................................................. 47
Mechanism of Action ............................................................................................................................................................... 47
R&D Progress ......................................................................................................................................................................... 47
Memantine + Buprenorphine - Drug Profile ................................................................................................................................. 48
Product Description................................................................................................................................................................. 48
Mechanism of Action ............................................................................................................................................................... 48
R&D Progress ......................................................................................................................................................................... 48
Memantine + Vivitrol - Drug Profile .............................................................................................................................................. 49
Product Description................................................................................................................................................................. 49
Mechanism of Action ............................................................................................................................................................... 49
R&D Progress ......................................................................................................................................................................... 49
Depot Naltrexone - Drug Profile................................................................................................................................................... 50
Product Description................................................................................................................................................................. 50
Mechanism of Action ............................................................................................................................................................... 50
R&D Progress ......................................................................................................................................................................... 50
Methylphenidate - Drug Profile .................................................................................................................................................... 51
Product Description................................................................................................................................................................. 51
Mechanism of Action ............................................................................................................................................................... 51
Opium (Opioid) Addiction – Pipeline Review, H1 2012 GMDHC1895IDB / Pub March 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(3)
Opium (Opioid) Addiction – Pipeline Review, H1 2012
R&D Progress ......................................................................................................................................................................... 51
Naltrexone - Drug Profile ............................................................................................................................................................. 52
Product Description................................................................................................................................................................. 52
Mechanism of Action ............................................................................................................................................................... 52
R&D Progress ......................................................................................................................................................................... 52
Tramadol - Drug Profile ............................................................................................................................................................... 53
Product Description................................................................................................................................................................. 53
Mechanism of Action ............................................................................................................................................................... 53
R&D Progress ......................................................................................................................................................................... 53
PPAR Gamma Agonist - Drug Profile .......................................................................................................................................... 54
Product Description................................................................................................................................................................. 54
Mechanism of Action ............................................................................................................................................................... 54
R&D Progress ......................................................................................................................................................................... 54
Methadone + Dextromethorphan - Drug Profile ........................................................................................................................... 56
Product Description................................................................................................................................................................. 56
Mechanism of Action ............................................................................................................................................................... 56
R&D Progress ......................................................................................................................................................................... 56
Methadone + Memantine - Drug Profile ....................................................................................................................................... 57
Product Description................................................................................................................................................................. 57
Mechanism of Action ............................................................................................................................................................... 57
R&D Progress ......................................................................................................................................................................... 57
Tramadol ER - Drug Profile ......................................................................................................................................................... 58
Product Description................................................................................................................................................................. 58
Mechanism of Action ............................................................................................................................................................... 58